<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26747">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918215</url>
  </required_header>
  <id_info>
    <org_study_id>CMRG-HF-1</org_study_id>
    <nct_id>NCT01918215</nct_id>
  </id_info>
  <brief_title>Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Heart Failure</brief_title>
  <acronym>CMR_GUIDE_HF</acronym>
  <official_title>Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flinders University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Australian Health and Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Flinders University</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contemporary heart failure (HF) guidelines recommend insertion of a primary prevention
      implantable defibrillator (ICD) in patients with left ventricular ejection fraction less
      than 35% (LVEF &lt; 35%) on maximally tolerated medical therapy. Nevertheless, there are a
      substantial number of HF patients who have LVEF&gt;35% and hence do not qualify for ICD, who
      succumb to sudden cardiac death (SCD). At present our tools to reliably risk stratify these
      patients with mild-moderate systolic dysfunction (LVEF 36-50%) are poor. It is likely that
      these patients have ventricular scar and/or replacement fibrosis as a substrate for their
      malignant arrhythmia. Cardiovascular magnetic resonance imaging (CMR) can reliably identify
      and quantify both ventricular scar (seen in Ischaemic cardiomyopathy, ICM) and replacement
      myocardial fibrosis (seen in Dilated Cardiomyopathy, DCM).

      Methods/Design: A multi-centre randomised controlled trial in which 433 patients with
      mild-moderate left-ventricular systolic dysfunction (either ICM or DCM) and ventricular
      scar/fibrosis on cardiovascular magnetic resonance are randomized to either ICD or
      implantable loop recorder (ILR) insertion and are followed up for 3 years. Potentially
      eligible patients will have a screening CMR and will be enrolled into the device arm of
      study based on the presence of any ventricular scar/fibrosis (CMR +). Patients who do not
      have ventricular scar/fibrosis will be followed up in an observational registry, and will
      not be randomised.

      The primary hypothesis is that among patients with mild-moderate HF, a routine CMR guided
      management strategy of ICD insertion is superior to a conservative strategy of standard
      care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Occurrence of Sudden Cardiac Death or Ventricular tachycardia leading to syncope</measure>
    <time_frame>At any time till 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sudden Cardiac Death</measure>
    <time_frame>At any time till 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syncopal Ventricular Tachycardia</measure>
    <time_frame>At any time till 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>At any time till 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association Functional class, Quality of life assessed by Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>3, 6,12, 24, 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure related hospitalizations</measure>
    <time_frame>At any time till 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic evaluation cost</measure>
    <time_frame>At end of study-36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">710</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Device Implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Registry</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD</intervention_name>
    <arm_group_label>Device Implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ILR</intervention_name>
    <arm_group_label>Device Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or greater than 18 years

          -  Patients with Coronary artery disease or dilated cardiomyopathy (idiopathic or
             familial type)

          -  Left ventricular systolic impairment as defined by left ventricular ejection fraction
             36-50% by any current standard technique (echocardiogram, multiple gated acquisition
             scan (MUGA), angiography

          -  Able and willing to comply with all pre-, post- and follow-up testing, and
             requirements

        Exclusion Criteria:

          1. History of cardiac arrest or spontaneous or inducible sustained ventricular
             tachycardia (VT )

          2. Standard Cardiac Magnetic Resonance imaging contraindications (e.g. severe
             claustrophobia)

          3. Currently implanted permanent pacemaker and/or pacemaker/ICD lead

          4. Moderate or severe renal insufficiency (eGFR&lt; 30mls/min)

          5. Recent Myocardial Infarction (MI) (&lt;40 days) or revascularization (&lt;90 days)

          6. New York Heart Association HF functional class IV at enrolment

          7. Conditions associated with life expectancy &lt;1 year

          8. Pregnancy or in females of child-bearing potential, the non-use of accepted forms of
             contraception

          9. Clinical indication for ICD or Pacemaker or cardiac resynchronisation therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph B Selvanayagam, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flinders Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph B Selvanayagam, MBBS</last_name>
    <phone>+61 8 8404 2195</phone>
    <email>joseph.selvanayagam@flinders.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joseph B Selvanayagam, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>April 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Flinders University</investigator_affiliation>
    <investigator_full_name>Joseph Selvanayagam</investigator_full_name>
    <investigator_title>Professor Joseph Selvanayagam</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
